Loading clinical trials...

Prospective Collection of Clinical Data and Human Body Material (HBM) of Cutaneous Melanoma and Non Melanoma Patients. Biobank Huidkanker | Clinical Trials | Clareo Health

RECRUITING

Prospective Collection of Clinical Data and Human Body Material (HBM) of Cutaneous Melanoma and Non Melanoma Patients. Biobank Huidkanker

Prospective Collection of Clinical Data and Human Body Material (HBM): Blood (Serum, Plasma, DNA) and Tissue of Cutaneous Melanoma and Non Melanoma Patients. Biobank Huidkanker

NCT07266142•Universitaire Ziekenhuizen KU Leuven

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to set up a prospective, fit-for-purpose collection of human body material (HBM)-blood (serum, plasma, DNA) and tissue-and standardized clinical data of patients with cutaneous melanoma and non-melanoma skin cancer. The main questions it aims to answer are: * To create a biobank with samples of human body material (HBM): blood (serum/plasma/DNA) and tissue and clinical data of patients with cutaneous melanoma and non-melanoma. * To support future research questions (after specific approval of the Ethics Committee) by using the biobank (through satellite protocols). If there is a comparison group: Not applicable (umbrella protocol for collection only). Participants will: * Share demographics, medical and surgical history, risk factors. * Complete Cancer Worry Scale questionnaire. * Provide biological samples: * Blood samples (serum, plasma, DNA). * Tissue samples (residual tissue or additional biopsy if consented).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
•Adult subjects (\>18 years of age) at time of enrolment.
•Subjects diagnosed with cutaneous melanoma or Non-melanoma skin cancer.
•Adult subjects able and willing to provide informed consent.

Exclusion Criteria

•Subjects unable or not willing to provide informed consent.

Locations (1)

UZLeuven, Department of Dermatology

Leuven, Vlaams-Brabant, Belgium

Key Dates

Start Date

November 17, 2025

Primary Completion Date

January 1, 2050

Completion Date

January 1, 2051

Last Updated

December 12, 2025

Enrollment

7,500

ESTIMATED participants

Conditions

Skin Cancer, Non-MelanomaSkin Cancer Melanoma

Interventions

Collection of Human Body Material and Clinical Data

OTHER

Contacts

Annemiek Leeman, Prof. Dr.

CONTACT

0032 016337950 annemiek.leeman@uzleuven.be

Sofie Van Kelst, BSc

CONTACT

0032 016337864 sofie.vankelst@kuleuven.be

Vitamin D Receptor Polymorphisms and Non-Melanoma Skin Cancer Risk

NCT03040492

Skin Cancer, Non-Melanoma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 12, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions